NCSL 2025 Resources

AdvaMed, The Medtech Association®, today released the following statements on the White House’s announcement today of a new initiative focused on women’s health research to be led by First Lady Jill Biden. This year, AdvaMed® created a Board-level committee to address health disparities more broadly, led by AdvaMed® Board of Directors member Lishan Aklog, M.D., as well as a Board-level subcommittee on women’s health, led by AdvaMed® Board member Tracy MacNeal. Statements from both medtech leaders follow.

“The Insight Series: AI & Digital Health” features industry experts answering key questions to help inform policymakers and the public about how AI is shaping the future of care delivery. Our latest edition features Julia Strandberg, Executive Vice President, Chief Business Leader, Connected Care at Philips.

WASHINGTON—AdvaMed®, The Medtech Association®, today announced a strategic event partnership with Informa, the global events leader and owner of the LSX portfolio of life sciences conferences, to strengthen collaboration across leading medtech convenings in the United States, Europe, and Asia-Pacific.

WASHINGTON—AdvaMed® announced today that nominations for its 2025 Lifetime Achievement Award as well as the AdvaMedDx Lifetime of Leadership & Service Award and theAdvaMed® Imaging Röntgen Award are open through April 10. All three of these annual awards will be presented during The MedTech Conference, Oct.18-21, 2026, in Boston. 

February is American Heart Month—a time to spotlight cardiovascular disease and highlight innovations that can improve patient outcomes. For the medtech community, it’s an opportunity to address persistent gaps in care through technology, data, collaboration, and policy advancement. Despite progress in treating heart conditions, sleep disorders—especially sleep apnea—remain a significant and underrecognized contributor to poor cardiovascular outcomes.1 Tackling this issue requires clinical awareness and supportive policies for timely diagnosis, coverage, and care beyond traditional settings.

AdvaMed® Digital Health Tech division member companies include world leaders in developing AI-enabled solutions to improve health and care, from diagnosis to treatment, clinical decision support, and wearables to wellness. “The Insight Series: AI & Digital Health” will feature company experts, answering pressing questions to inform policymakers and the public about how AI and digital health are transforming care and delivery. Our inaugural entry is a conversation between Melissa Cha of Amazon and Taha Kass-Hout of GE HealthCare.

In a new video developed in partnership with Patients Rising, AdvaMed’s Peter Weems, Vice President of Imaging Government Affairs and Policy Strategy, explains why the Health Tech Investment Act is critical to expanding patient access to FDA-authorized AI-enabled medical devices.

NAPLES, Fla., Dec. 4, 2025 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that its Catalyst Fracture Shoulder System has received FDA 510(k) clearance for additional indications that now include anatomic (total or hemi) shoulder procedures, giving surgeons flexibility to treat complex proximal humeral fractures (PHFs) with a single, streamlined platform for both anatomic and reverse replacements. In anatomic indications, the Catalyst Fracture System utilizes Catalyst’s ellipsoid head design, shown to better restore natural anatomy compared to traditional spherical head designs on the market today.